Activity Dates: 10/07/2022 - 10/07/2025
If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric patients, we invite you to participate in this online course.
Any co-occurring substance use increases the difficulty in determining the best treatment approach, however, AUD and OUD were listed as one of the most common co-occurring SUD that many pharmacists encounter in clinical practice. The target audience for this topic would be those familiar with individual treatment of AUD and OUD who may want to further explore the complications and intricacies of treating these disorders when they are co-occurring.
Both AUD and OUD have FDA approved medications and clear guidelines which guide treatment of these disorders individually. However, when these disorders are co-occurring, treatment can become more complicated. The medical community has largely focused on OUD during the epidemic even though most patients with substance use disorder use multiple substances, and the presence of multiple substance use disorders is associated with worse treatment outcomes. Because problematic alcohol and opioid use are traditionally studied as independent conditions, limited evidence-based strategies exist for mitigation of alcohol-related risk among patients with OUD. Comorbid OUD and AUD are known to interfere with medication adherence and to be associated with increased morbidity and mortality.
The presence of chronic pain is also known to complicate both AUD and OUD and to be associated with poorer outcomes. Recent studies have started to consider the effect of pain on alcohol treatment outcomes. Jakubczyk and colleagues (2016) found reductions in physical pain during alcohol treatment predicted lower risk of alcohol relapse during the 4 weeks following treatment. Similarly, Witkiewitz and colleagues (2015) found pain interference and pain intensity at the end of treatment significantly predicted heavy drinking and time to first heavy drinking day during and following treatment.
Naltrexone is the only medication currently indicated to treat AUD and OUD. In a patient who is not able or not willing to take naltrexone, there may be a need to consider other medications for OUD and AUD as monotherapy or in combination. It can be difficult to determine if one treatment should take precedence or to manage concurrently.
One significant concern is that treatment of OUD with an opioid agonist medication (buprenorphine or methadone) may be dangerous in combination with alcohol. A case-control cohort study found that treatment of OUD with opioid agonists is associated with fewer admissions for alcohol-related acute events in patients with OUD with co-occurring AUD.
To receive ACPE credit for this session, you must:
Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 7 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Michelle Colvard, PharmD, BCPPView biographical information and disclosures
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
2022 Planning Committee
Ericka Crouse, PharmD, BCPP, BCGP, FASHP, FASCP
VCU School of Pharmacy
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: ASHP - PAM Behavioral Health Committee (volunteer),
Editorial Board - The Medical Letter (paid), American Society of Consultant Pharmacists - speak at meetings/webinars on GeroPsych topics (paid),
Wolters-Kluwer, paid consultant
Cassandra Davis, PharmD, BCPP, BCPS
Mental Health Clinical Pharmacy Specialist
Orlando VA Medical Center
No Relevant Financial Relationships to Disclose
Megan J. Ehret, PharmD, BCPP, MS
BCPP Program Director
University of Maryland
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Psych U Section Advisor,
SMI Adviser; Pharmacist Consultant
Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral Health Department, NIH
Sarah Melton, PharmD, BCPP, BCACP, FASCP
Professor of Pharmacy Practice
Gatton College of Pharmacy
Johnson City, TN
Non-Financial Interests: One Care of Southwest Virginia, Virginia Board of Pharmacy, Virginia Opioid Abatement Authority,
Virginia Department of Health Professions Board, Virginia Medicaid Pharmacy and Therapeutics Committee
Troy Moore, PharmD, MS, BCPP
Erika Titus-Lay, PharmD, BCPP, BCPS
California Northstate University College of Pharmacy
Elk Grove, CA
Educational Grants, Research Grants or Contracts: Sponsor, ASHP Pharmacy Leadership Scholars Research Grant
Audrey Abelleira, PharmD, BCPP, BCPS
David Dadiomov, PharmD, BCPP
James J. Gasper, PharmD, BCPP
Cindy A. Gutierrez, PharmD, MS, BCPP
Dara L. Johnson, PharmD, BCPP, BCACP
Benjamin Miskle, PharmD
Marnie Noel, PharmD, BCPP
All relevant relationships have been mitigated.
All relevant relationships have been mitigated.
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: My presentation will include discussion of off-label, experimental, and /or investigational use of drugs or devices: off-label use of gabapentin, topiramate for alcohol use disorder
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.